WO2002015809A2 - Dental composition for hypersensitive teeth - Google Patents
Dental composition for hypersensitive teeth Download PDFInfo
- Publication number
- WO2002015809A2 WO2002015809A2 PCT/US2001/026073 US0126073W WO0215809A2 WO 2002015809 A2 WO2002015809 A2 WO 2002015809A2 US 0126073 W US0126073 W US 0126073W WO 0215809 A2 WO0215809 A2 WO 0215809A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- accordance
- composition
- potassium
- blocking agent
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/20—Protective coatings for natural or artificial teeth, e.g. sealings, dye coatings or varnish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8158—Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
Definitions
- the invention relates to compositions for the treatment of dentinal hypersensitivity and methods for treating dentinal hypersensitivity.
- Dentinal hypersensitivity is a temporary induced pain sensation produced when hypersensitive teeth are subjected to changes in temperature and/or pressure or to chemical action. Hypersensitivity may occur whenever the dentin of a tooth is exposed by attrition or abrasion, or when the tooth's finer root surface is exposed by periodontal disease. Dentin is a bone-like material in teeth that is usually covered by enamel above the gum line and cementum below the gum line. The enamel or cementum may be removed through decay, injury, disease or other causes, thereby exposing the dentin to external stimuli in the mouth. Dentin generally contains channels, called tubules, that allow material and energy transport between the exterior of the dentin and the interior of the tooth where the nerve is located.
- dentinal hypersensitivity suggests that exposure of these tubules to external stimuli can cause irritation of the nerve and lead to the discomfort of hypersensitivity.
- the hydrodynamic theory suggests that hypersensitivity may be treated by making the nerve in the tooth less sensitive to stimuli, or by blocking or occluding the tubules to prevent or limit exposure of the nerve to external stimuli.
- Many attempts have been made to control dentinal hypersensitivity.
- One approach is to reduce the excitability of the nerve in a sensitive tooth. This technique interferes with the ordinary triggering process of the neive by altering the chemical environment of the nerve through the use of agents to make the nerve less sensitive. These agents are generally referred to as "nerve agents" or “nerve desensitizing agents”.
- the most well-known agent for this purpose is potassium nitrate, used in commercial dentifrices for sensitive teeth and discussed in U.S. Patent No. 3,863,006.
- potassium salts such as potassium bicarbonate and potassium chloride, USP Nos. 4,631,185 and 4,751,072
- strontium and fluoride ions USP No. 4,990,327: zinc and strontium ions, USP No. 3,888,976.
- Another approach to control dentinal hypersensitivity is the use of agents to fully or partially occlude tubules.
- tubule blocking agents examples include charged polystyrene beads, USP No. 5,211,939; apatite, USP Nos. 4,634,589 and 4,710,372;. a polyacrylic acid polymer having a typical molecular weight from about 450,000 to about 4,000,000, USP No. 5,270,031 ; and water-soluble or water-swellable polyelectrolytes or salts thereof, USP No. 4,362,713.
- U.S. Patent No. 5,589,159 discloses the use of Laponite or hectorite clay to seal dentinal tubules.
- PCT Patent Application WO 00042981 discloses a different mode of action wherein a composition of two different desensitizing agents (stannous fluoride and potassium nitrate) is separated in a dual phase dispensing unit. These agents are separated in the disclosed compositions to enhance their stability.
- the inventors have surprisingly found a highly effective treatment of dentinal hypersensitivity in a composition that combines a nerve desensitizing agent with a tubule blocking agent, preferably a combination of two tubule blocking agents, thereby providing a synergistic effect over the prior art methods of employing either a nerve agent or a tubule blocking agent alone, or a nerve agent combined with a second chemical desensitizer.
- the invention provides a composition for desensitizing teeth comprising a desensitizing amount of: a) at least one tubule blocking agent, preferably a combination of two such agents; and b) a nerve desensitizing agent selected from the group consisting of at least one potassium salt, at least one strontium salt, and mixtures thereof, wherein the tubule blocking agent deposits or swells upon the dentinal surface and/or precipitates within the dentinal tubules, retaining a higher concentration of the nerve desensitizing agent at the exposed dentinal surface and within the dentinal tubules.
- the invention further provides a method for desensitizing hypersensitive teeth by applying thereto a desensitizing amount of an oral composition
- a desensitizing amount of an oral composition comprising: a) a nerve desensitizing amount of at least one tubule blocking agent, preferably a combination of two such agents; and b) a desensitizing agent selected from the group consisting of consisting of at least one potassium salt, at least one strontium salt, and mixtures thereof.
- This invention also discloses a method for preparing a composition for desensitizing teeth comprising a desensitizing amount of at least one tubule blocking agent, preferably a mixture of at least two tubule blocking agents, and a nerve desensitizing agent selected from the group consisting of at least one potassium salt, at least one strontium salt, and mixtures thereof.
- the inventors have found a highly effective treatment of dentinal hypersensitivity in a composition that combines a tubule blocking agent with a nerve desensitizing agent, providing a synergistic and sustained effect over the prior art methods of employing either a nerve agent, a mixture of nerve agents, or a tubule blocking agent alone.
- the first component of the subject is at least one tubule blocking agent, preferably a combination of two such agents as will be described hereinbelow, which serves to seal or block the dentin tubules thereby diminishing the effect of external stimuli such as changes in temperature, pressure, ionic gradients or contact with chemical irritants, as well as helping to reduce the flushing of potassium from the tubules by natural outward flow of dentinal fluid.
- tubule blocking agents include: materials having a particle size smaller than that of a dentin tubule for blocking the dentin tubules; and materials that can produce an agglomerate within the dentin tubules and/or form a precipitate that will deposit onto the dentinal surface.
- super-absorbent acrylic polymers having a particle size smaller than that of a dentin tubule are used as tubule blocking agents.
- Super-absorbent acrylic polymers are substantially water-insoluble, cross- linked, partially neutralized polymers that have been typically used in diapers, feminine hygiene articles and surgical dressings. They generally have a gel capacity of at least about 50 grams of deionized water per gram at 20°C and often at least about 100 grams, 200 grams or more of water per gram diy weight of polymer at 20°C.
- Super-absorbent polymers may be a homopolymer of acrylic acid, or may be formed from a water- soluble blend of monoethylenically unsaturated monomers selected in known manner such that the final cross-linked polymer is water-absorbent.
- Such monomer blends may be nonionic, anionic, or cationic.
- Suitable cationic monomers that can be employed include acrylamides and dialkylaminoalkylmethacrylates, generally in the form of acid addition or quaternaiy ammonium salts.
- Nonionic monomers that can be employed include methacrylamide and the like.
- Super-absorbent polymers may be, for example, a homopolymer of acrylic acid or may be formed from a water-soluble blend of monoethylenically unsaturated monomers selected in known manner so that the final cross-linked polymer is water- absorbent.
- Such monomer blends may be nonionic, anionic, or cationic.
- Suitable cationic monomers that can be employed include acrylamides and dialkylaminoalkylmethacrylates, generally in the form of acid addition or quaternary ammonium salts.
- Nonionic monomers that can be employed include methacrylamide and the like.
- Anionic monomers that can be employed include acrylic acid and the like.
- Preferred super-absorbing polymers for use as tubule blocking agents are cross-linked emulsion polymers of acrylic acid and copolymers of acrylic acid with acrylamide.
- the particle size of the super-absorbent polymers utilized as tubule blocking agents is typically from about 0.5 to about 2.0 microns at their largest dimension before water absorption. Since the particles are irregular in shape, it will be understood that, so long as the particles are effective as tubule blocking agents, the size will be appropriate to the practice of the invention.
- acrylic polymers that can agglomerate within or over the dentin tubules are used as tubule blocking agents. Such polymers of polyacrylic acids or salts thereof are commonly used as binders in pharmaceutical and cosmetic formulations.
- Carbomers are a group of acrylic polymers that exhibit excellent general gelation properties and can act as mucoadhesives and counterirritants in formulations.
- Carbopol® Commercially available under the trade name of Carbopol® from B F Goodrich.
- a preferred commercially available polymer for use as a tubule blocking agent is a polyacrylate polymer sold by B F Goodrich under the trade designation Carbopol® 980. It has been reported that certain Carbopol® polymers at concentrations of about 4% and above are effective against hypersensitivity. However, at this high concentration, and due to the thick mucilaginous nature of the gel formed upon application, the organoleptics of such polymers are not favorable.
- tubule blocking agents are polymers having closely associated hydrophilic and hydrophobic regions.
- polymer is intended to encompass both homopolymers and copolymers.
- Copolymers may include alternating copolymers, random copolymers, statistical copolymers, graft copolymers and block copolymers.
- the tubule blocking agent is a homopolymer or an alternating copolymer, and more preferably an alternating copolymer.
- the copolymer may be linear, or branched, or even crosslinked to form a network polymer.
- the copolymer has at least one hydrophilic monomer capable of forming a salt, and most preferably, the copolymer comprises a monovalent cation salt of a hydrophobic/hydrophilic copolymer that disperses into micelles in aqueous systems.
- the hydrophobic monomer of the tubule blocking agent in this embodiment is preferably a long chain -olefin while the hydrophilic monomer is preferably a strongly hydrophilic monomer that causes its associated copolymer form to create micelles.
- Preferred hydrophilic monomers are highly hydrophilic, salt-forming monomers, such as carboxylic acids and diacids- Most highly preferred hydrophilic monomers are diacids, such as maleic acid. Other anionic polymeric salts may also be used.
- the copolymer is a regular copolymer that alternates between the two types of monomer in the copolymer chain.
- the tubule blocking agent in the second embodiment is preferably a polysoap,
- One monomer is highly hydrophobic and preferably is a long chain -olefin comprising a carbon chain of at least about eight (8), preferably at least about ten (10) and more preferably at least about twelve (12) carbon atoms.
- the second monomer is hydrophilic in character and preferably consists of a maleic acid or anhydride moiety.
- the tubule blocking agent in this second embodiment can be structurally represented as follows:
- R is a long chain aliphatic group comprised of a higher alkyl group, for example a hexyl group, i.e. the ⁇ -olefin monomer chain is C 8 , or an octyl group, i.e. the ⁇ -olefin monomer chain is do, or longer group and M + is a monovalent cation, preferably sodium, potassium, ammonium, choline, lysine, triethanolamine and mixtures thereof.
- the hydrophobic/hydrophilic copolymer as a tubule blocking agent can comprise any number of repeating monomeric units.
- the copolymer would have a molecular weight of from about 2,000 to about 1 ,000,000 daltons, preferably about 5,000 to about 500,000 daltons, and most preferably about 10,000 to about 100,000 daltons.
- the copolymer is the hydrolysis product of an alternating long chain ⁇ -olefin-co-maleic anhydride copolymer wherein the ⁇ -olefin has at least about ten carbons and even more preferably at least about twelve carbons (e.g., 2 H 2 ) or higher.
- copolymers of this nature include but not limited to tetradecene/maleic anhydride copolymer, octadecene/maleic anhydride copolymer, triacontene/maleic anhydride copolymer, and mixtures thereof.
- the tubule blocking agent is Chevron/Gulf PA- 18® brand polyanhydi ⁇ de resin, an alternating copolymer of a 1: 1 molar ratio of maleic anhydride and 1-octadecene (CAS: "1-octadecene polymer with 2,5-furandione"; INCA: octadecene/MA copolymer).
- the resin has an average molecular weight from about 10,000 to about 60,000 daltons.
- Preferred for use as a tubule blocking agent is the hydrolyzed cation salt of this copolymer, especially the monovalent salts thereof.
- Preferred monovalent salts are the alkali salts and most preferably the sodium or potassium salts thereof and the monovalent cations of ammonium, u ⁇ ethanolamine, choline and lysine. It has been found in accordance with the present invention that a combination of the previously described two groups of tubule blocking agents is unexpectedly advantageous and enhances the overall beneficial action of the subject compositions as desensitizing agents. More particularly, combining the copolymers having alternating hydrophilic and hydrophobic monomers, e.g. a long chain ⁇ -olefin hydrophobic monomer and a salt-forming carboxylic acid or diacid hydrophilic monomer, with super-absorbent acrylic acid polymers, e.g.
- polyacrylate polymers results in a tubule blocking component having enhanced efficacy.
- the addition of the copolymer to the polyacrylate polymers allows the latter to be present in a lower concentration, yet maintain or even somewhat enhance its relative effectiveness without the previously reported disadvantage of undesirable organoleptic properties.
- enhanced properties are realized from combining the polyacrylate polymer blocking agent in a concentration not exceeding about two percent by weight of the composition, preferably from about 0.5 to about 2 percent by weight with the above-described hydrophobic/hydrophilic copolymer in a weight ratio of from about 1 : 1 to 1 : 10, preferably from about 1 : 1 to 1 :6, most preferably from about 1 :2 to 1:6.
- This combination is also advantageous in that it is particularly robust or stable in the presence of the inorganic salts of the nerve desensitizing agents, especially the potassium salts, in comparison to other know tubule blocking agents.
- tubule blocking agent can be used besides those described above, including water-soluble or water-swellable polyelectrolyte partial salt such as polyacrylic acid polymers having molecular weight of 400,000 or more under the tradename of Carpobol® or Noveon®, or cationically charged colloidal particles such as alumina coated silica commercially available under the trademark Nalco®, or soaps such as alkyl phosphates and coco fatty acid soaps (the latter working by a mechanism similar to soap scum formation with endogenous calcium in the oral environment).
- the tubule blocking agents are incorporated in the composition in a desensitizing effective amount.
- tubule blocking agents will be in an amount of about 0.1 to 15 wt. , usually from about 0.4 to 10 % and most preferably from about 2 to 8 wt. %.
- Phosphate, coco and alike soaps such as MAPS (Rhodia) may be incorporated to further enhance the physical occlusion. Larger amounts of the tubule blocking agent can also be employed if desired.
- the second synergistic component of the subject composition s anti- hypersensitivity agents, also known as nerve desensitizing agents.
- nerve desensitizing agents are suitable for use in conjunction with the tubule blocking agent for a synergistic effect.
- the nerve desensitizing agents which are neurally active with analgesic activity, when trapped in the tubules by the effect of the first component tubule blocking agents, effectively act on the nerve to make the nerve less sensitive, hence reducing the effect on the nerve of any external factors that are able to penetrate the tubules.
- Any nerve desensitizing agent that is a neuroactive substance, i.e., any ion or salt that has a pain reducing or analgesic activity is suitable for use in the composition of the present invention.
- Suitable nerve desensitizing agents include, without intended limitation, potassium or strontium salts, including potassium bicarbonate, potassium citrate, potassium chloride, potassium nitrate, strontium chloride, strontium acetate, strontium nitrate, and potassium or strontium salts of other similar conjugate acids, and mixtures thereof.
- potassium or strontium salts including potassium bicarbonate, potassium citrate, potassium chloride, potassium nitrate, strontium chloride, strontium acetate, strontium nitrate, and potassium or strontium salts of other similar conjugate acids, and mixtures thereof.
- at least one potassium salt and/or at least one strontium salt are used in combination with a source of physiologically acceptable fluoride ion such as stannous fluoride, sodium fluoride, potassium fluoride, mixtures thereof or the like.
- the nerve desensitizing agent is incorporated in a desensitizing effective amount. This will vary depending on the particular type and form of oral composition and other materials present, including the first essential component of tubule blocking agent but most often, the nerve agent will be in an amount of about 0.1 to 15 wt. %, usually from about 0.3 to 10 % and most preferably from about 2 to 8 wt. %.
- the oral compositions of the present invention are typically formulated in the form of tooth pastes or gel dentifrices to be brushed on the teeth, or in the form of mouthwashes.
- the desensitizing agent can be formulated into a tooth powder, dentifrice, mouthwash, lozenge, buccal adhesive patch, oral spray, coatings or chewing gum.
- these delivery forms are prophetic, higher or lower amounts of these agents may be combined to achieve the desired effect.
- the formulations containing the desensitizing combinations of the present invention may contain additional ingredients typically incorporated into oral health care compositions. Suitable ingredients include, without intended limitation, abrasive polishing materials, sudsing agents, flavoring agents, humectants, binders, sweetening agents, and water.
- Abrasives which may be used in the compositions of the invention include alumina and hydrates thereof, such as alpha alumina trihydrate, magnesium trisilicate, magnesium carbonate, aluminosilicate, such as calcined aluminum silicate and aluminum silicate, calcium carbonate, zirconium silicate, polymethylmethacrylate, powdered polyethylene, silica xerogels, hydrogels and aerogels and the like.
- abrasive agents are calcium pyrophosphate, insoluble sodium metaphosphate, calcium carbonate, dicalcium orthophosphate, particulate hydroxyapatite and the like.
- the abrasive may be present in an amount of from 0 to 70% by weight, preferably 1 to 70% by weight, more preferably from 10 to 70% by weight, particularly when the composition is formulated into a toothpaste.
- Humectants contemplated for use in the subject compositions include polyols, such as glycerol, sorbitol, polyethylene glycols, propylene glycol, hydrogenated partially hydrolyzed polys accharides and the like.
- the humectants are generally present in amounts of from 0 to 80%, and preferably 5 to 70% by weight for toothpastes.
- Thickeners suitable for use in the invention typically silica, may be present at a level from about 0.1 to 20% by weight.
- Binders suitable for use in the compositions of the invention include hydroxyethyl cellulose, and hydroxypropyl cellulose, as well as xanthan gums, Iris moss and gum tragacanth. Binders may be present in the amount from 0.01 to 10%.
- Sweeteners suitable for use, e.g. saccharin may be present at levels of about 0.1% to 5%.
- Fluoride sources commonly used in oral health care compositions such as sodium fluoride, stannous fluoride, sodium monofluorophosphate, zinc ammonium fluoride, tin ammonium fluoride, calcium fluoride and cobalt ammonium fluoride may be included for delivering anti-caries benefit.
- Preferred compositions in accordance with the present invention will include a fluoride source.
- Fluoride ions are typically provided at a level of from 0 to 1500 ppm, preferably 50 to 1500 ppm, although higher levels up to about 3000 ppm may be used.
- Surfactants such as a soap, anionic, nonionic, cationic, amphoteric and/or zwitterionic, may be present within the range of 0 to 15%, preferably 0.1 to 15%, more preferably 0.25 to 10% by weight.
- Anionic and/or nonionic surfactants are most preferced, such as sodium lauryl sulfate, sodium lauroyl sarcosinate and sodium dodecylbenzene sulfonate.
- Suitable flavors are usually included in low amounts, such as from 0.01 to about 5% by weight, especially from 0.1 % to 5%.
- compositions in accordance with the present invention may, and preferably will, include antibacterial agents include for example phenolics and salicylamides, and sources of certain metal ions such as zinc, copper, silver and stannous ions, e.g. zinc, copper and stannous chloride, and silver nitrate.
- antibacterial agents include for example phenolics and salicylamides, and sources of certain metal ions such as zinc, copper, silver and stannous ions, e.g. zinc, copper and stannous chloride, and silver nitrate.
- Dyes / colorants suitable for oral health care compositions i.e. FD & C Blue #1, FD & C Yellow #10, FD & C Red #40, etc.
- Various other optional ingredients may be included in the compositions of the invention such as preservatives, vitamins such as vitamin C and E, other anti-plaque agents such as stannous salts, copper salts, strontium salts and magnesium salts.
- pH adjusting agents such as calcium glycerophosphate, sodium trimetaphosphate
- anti-staining compounds such as silicone polymers, plant extracts and mixtures thereof.
- polymers particularly anionic polymers, such as polycarboxylates or polysulfonates, or polymers containing both a carboxylate and a sulfonate moiety, phosphonate polymers or polyphosphates may be included.
- compositions suitable for oral care compositions, e.g., toothpastes, gels, mouthwashes, gums, powders, etc. Except where otherwise noted, references to toothpastes are to be construed as applying to gels as well. Mouthwash forms, mouthwashes and similar preparations may be formulated as well. Such preparations typically comprise a water/alcohol solution, including a flavor component, humectant, sweetener, sudsing agent, and colorant.
- a water/alcohol solution including a flavor component, humectant, sweetener, sudsing agent, and colorant.
- Mouthwashes can include ethanol at a level of from 0 to 60%, preferably from 5 to 30% by weight.
- compositions in accordance with the present invention containing the subject advantageous desensitizing combinations can be prepared by conventional methods of making oral health care formulations, typically combining the various ingredients in a manner and order recognized in the art of compounding such formulations as being convenient to achieve the desired effects.
- a gel may be formulated by combining a suitable gelling agent with water to form the gel, combining the remaining ingredients therein and finally making whatever adjustments in volume, appearance and the like as would be conventionally carried out to achieve an elegant dentifrice preparation.
- compositions containing two preferred tubule blocking agents are advantageously prepared by separately neutralizing them with heat in the presence of a base to form premixes, adding the cross-linked acrylic polymer premix to the premix containing the hydrolysis product of an alternating copolymer of a long-chain ⁇ -olefin and maleic anhydride premix and then adding the remaining ingredients, including the nerve desensitizing agent, for the desired preparation in a conventional manner.
- the alternating copolymer is neutralized as above with an excess of base and then the acrylic polymer is added thereto under high sheer, thereby neutralizing it with the excess base. It has been found that other methods of combining these ingredients do not provide the same level of stability and activity.
- the combined tubule blocking agents formed by either method described above are mixed with the nerve desensitizing agent, i.e. potassium nitrate, sodium fluoride, sodium saccharin and non-ionic detergent for 10 minutes at temperature of about 50°C or higher. Under further cooling (at about 25° C or lower), glycerin and gums are mixed in for 20 minutes. Titanium dioxide, binder and abrasive are blended in for thirty minutes. Detergent and flavor are then blended in, under vacuum, for another 20 minutes.
- the nerve desensitizing agent i.e. potassium nitrate, sodium fluoride, sodium saccharin and non-ionic detergent
- the nerve desensitizing agent i.e. potassium nitrate, sodium fluoride, sodium saccharin and non-ionic detergent for 10 minutes at temperature of about 50°C or higher.
- glycerin and gums are mixed in for 20 minutes. Titanium dioxide, binder and abrasive are blended in for thirty minutes. Detergent and flavor
- the oral compositions of the present invention are preferably prepared as described above.
- the composition may be packaged in a conventional plastic laminate, metal tube or dispenser, or be packaged in separate phases to enhanced appearance. It may be applied to dental surfaces by any physical means, such as a toothbrush, fingertip or by an applicator directly to the sensitive area. Mouthwashes according to the present invention may be presented for use as a conventional gargle or may be packaged in a suitable delivery vehicle for use as a mouth spray. Solid dosage forms examples include pastilles, lozenges, chewing gums, tablets, mouthstrips, balms and the like.
- Dentifrice formulations were prepared using the ingredients set forth in Table 1.
- the composition designated Example 209 employs a polyacrylate polymer as a tubule blocking agent in combination with potassium nitrate.
- the composition of Example 276 employs both polyacrylate and polyanhydride copolymer with potassium chloride, whereas that of Example 271 employs potassium nitrate with the combination of both tubule blockers, i.e. the polyanhydride copolymer (PA 18) and the polyacrylate polymer.
- PA 18 polyanhydride copolymer
- one placebo example identical to Example 271 was prepared without any tubule blockers with the rest of the ingredients being adjusted proportionally to add up to 100 %.
- Examples 209 and 212 contain comparatively low concentrations of the polyacrylate tubule blocking agent, but are organoleptically acceptable. The formulation of the various Examples is shown in Table 1.
- Each disc is mounted into the split chambered device described by Pashley which is a special leak-proof chamber connected to a pressurized fluid reservoir containing a tissue culture fluid.
- a pressurized fluid reservoir containing a tissue culture fluid.
- the fluid can be made at physiological pH.
- the discs are wetted with human saliva to approximate intra-oral conditions.
- the apparatus includes a gas capillary tube mounted on a ruler or other measuring instrument. An air bubble is injected into the glass capillary tube. By measuring the displacement of the bubble as a function of time, fluid flow through the dentin disc can be measured.
- an experimental dentifrice is applied to the external surface with a nylon brush. After a defined period of brushing, the experimental material is rinsed off, and the post- application hydraulic conductance is measured. In this fashion, the ability of various experimental materials both alone and as components of dentifrice systems can be tested for the ability to obstruct fluid flow in the dentinal tubules.
- the percent flow reduction induced by brushing with the experimental materials using the dentifrice formulations shown in the Examples shown in Table 1 are presented in Table 2.
- Formulations including those containing a combination of tubule blocking agents in accordance with the present invention with a desensitizing agent were tested as described in Example 1 for hydraulic conductance. Only one desensitizing agent was utilized in each formulation. The results are given in Table 4.
- Poloxamer 407 (Pluronic® F-127) 2
- a chewing gum in accordance with the invention may be made using the formulation below.
- the chewing gum base will be softened at 65 ° C. using a sigma blade mixer, cooled to 60 ° C. and 3/5 of the sorbitol powder and calcium saccharin will then be added, followed by the glycerin. Then 1/5 of the sorbitol powder, 1/2 of the lecithin and the superabsorbent polymer will be added. After cooling to 50° C, the rest of the sorbitol powder, lecithin, and flavor will be added. The mixture may then be rolled into patties and cut into strips.
- Flavor 1 DP6-6983 (Cross-linked polyacrylate) 3
- a lozenge in accordance with the invention may be made using the formulation below.
- the sorbitol and xylitol are heated at 1.65 ° C. until the base begins to thicken.
- the combination is cooled to 140 ° C. and the citric acid added.
- the gelatin is added and after cooling to 50 ° C, the flavor and superabsorbent polymer are added. Cooling is continued and a seed crystal of sorbitol is added to start crystallization.
- the mixture is then poured into molds to form lozenges.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001286581A AU2001286581A1 (en) | 2000-08-21 | 2001-08-21 | Dental composition for hypersensitive teeth |
EP01966037A EP1331919A4 (en) | 2000-08-21 | 2001-08-21 | Dental composition for hypersensitive teeth |
JP2002520724A JP2004506663A (en) | 2000-08-21 | 2001-08-21 | Dental composition for sensitive teeth |
US10/344,074 US20030215401A1 (en) | 2000-08-21 | 2001-08-21 | Dental composition for hypersensitve teeth |
CA002420154A CA2420154A1 (en) | 2000-08-21 | 2001-08-21 | Dental composition for hypersensitive teeth |
US11/554,374 US20070059257A1 (en) | 2000-08-18 | 2006-10-30 | Dentinal composition for hypersensitive teeth |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64240800A | 2000-08-21 | 2000-08-21 | |
US09/642,408 | 2000-08-21 | ||
US09/850,352 US20020041852A1 (en) | 2000-08-18 | 2001-05-07 | Dental composition for hypersensitive teeth |
US09/850,352 | 2001-05-07 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/850,352 Continuation US20020041852A1 (en) | 2000-08-18 | 2001-05-07 | Dental composition for hypersensitive teeth |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/554,374 Continuation US20070059257A1 (en) | 2000-08-18 | 2006-10-30 | Dentinal composition for hypersensitive teeth |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002015809A2 true WO2002015809A2 (en) | 2002-02-28 |
WO2002015809A3 WO2002015809A3 (en) | 2002-06-06 |
Family
ID=27094007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/026073 WO2002015809A2 (en) | 2000-08-18 | 2001-08-21 | Dental composition for hypersensitive teeth |
Country Status (7)
Country | Link |
---|---|
US (1) | US20030215401A1 (en) |
EP (1) | EP1331919A4 (en) |
JP (1) | JP2004506663A (en) |
AR (1) | AR030713A1 (en) |
AU (1) | AU2001286581A1 (en) |
CA (1) | CA2420154A1 (en) |
WO (1) | WO2002015809A2 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1390004A2 (en) * | 2001-05-03 | 2004-02-25 | Block Drug Company, Inc. | Dental composition for treating hypersensitive teeth |
EP1599182A2 (en) * | 2003-02-21 | 2005-11-30 | Rhodia Inc. | Anti-sensitivity, anti-caries, anti-staining, anti-plaque, ultra-mild oral hygiene agent |
US7090882B2 (en) | 2003-06-12 | 2006-08-15 | Cargill, Incorporated | Antimicrobial salt solutions for food safety applications |
WO2006100071A1 (en) | 2005-03-21 | 2006-09-28 | Glaxo Group Limited | Alkyl sulfate free and orthophosphate free dentifrice compostion comprising a fluoride source and a silica dental abrasive |
WO2009106972A2 (en) * | 2008-02-26 | 2009-09-03 | Italmed S.R.L. | Dental composition for desensitizing, disinfecting and protecting exposed dentine |
WO2010112577A1 (en) | 2009-04-03 | 2010-10-07 | Glaxo Group Limited | Antibacterial composition comprising 4 -isopropyl-3-methylpheno and zinc ions |
WO2011009867A2 (en) | 2009-07-22 | 2011-01-27 | Glaxo Group Limited | Novel composition |
WO2011073229A1 (en) | 2009-12-17 | 2011-06-23 | Glaxo Group Limited | Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity |
WO2011120943A2 (en) | 2010-03-31 | 2011-10-06 | Glaxo Group Limited | Novel composition |
WO2013020960A2 (en) | 2011-08-09 | 2013-02-14 | Glaxo Group Limited | Novel composition |
WO2013034196A1 (en) * | 2011-09-09 | 2013-03-14 | Gaba International Holding Ag | Stable compositions and methods for preparing the same |
RU2526148C2 (en) * | 2008-09-30 | 2014-08-20 | Глаксо Груп Лимитед | Toothpaste composition |
WO2014124950A1 (en) | 2013-02-14 | 2014-08-21 | Glaxo Group Limited | Novel composition |
US8900558B2 (en) | 2006-06-30 | 2014-12-02 | Colgate-Palmolive Company | High fluoride ion oral care composition and method for maintaining anticaries activity |
WO2015065968A1 (en) * | 2013-10-28 | 2015-05-07 | The Procter & Gamble Company | Oral care compositions for tooth desensitizing |
EP2413882B1 (en) | 2009-04-01 | 2016-11-16 | Colgate-Palmolive Company | Dual action dentifrice compositions to prevent hypersensitivity and promote remineralization |
CN106794132A (en) * | 2014-08-29 | 2017-05-31 | 日油株式会社 | Dental hypersensitiveness's mitigation oral cavity composition |
WO2019068596A1 (en) | 2017-10-02 | 2019-04-11 | Glaxosmithkline Consumer Healthcare (Uk) Ip Limited | Novel composition |
WO2019115601A1 (en) | 2017-12-15 | 2019-06-20 | Glaxosmithkline Consumer Healthcare (Uk) Ip Limited | Novel composition |
WO2020007888A1 (en) | 2018-07-05 | 2020-01-09 | Glaxosmithkline Consumer Healthcare (Uk) Ip Limited | Dentifrice comprising carboxylic acid or alkali metal salt thereof and a source of free fluoride ions |
WO2020007887A1 (en) | 2018-07-05 | 2020-01-09 | Glaxosmithkline Consumer Healthcare (Uk) Ip Limited | Dentifrice comprising a pvm-ma copolymer and a source of free fluoride ions |
WO2023094489A1 (en) | 2021-11-29 | 2023-06-01 | Glaxosmithkline Consumer Healthcare (Uk) Ip Limited | Non-aqueous dentifrice composition |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9139731B2 (en) | 1999-11-12 | 2015-09-22 | The Procter & Gamble Company | Compositions and methods for improving overall tooth health and appearance |
JP2006056846A (en) * | 2004-08-23 | 2006-03-02 | Sun Medical Co Ltd | Bleaching agent kit for tooth for suppressing hyperesthesia in bleaching |
US20060153949A1 (en) * | 2005-01-11 | 2006-07-13 | Cadbury Adams Usa Llc. | Edible compositions containing swellable polymers |
US20060193946A1 (en) * | 2005-02-25 | 2006-08-31 | Cadbury Adams Usa Llc. | Edible compositions containing gelling silicates |
US20080112902A1 (en) * | 2005-04-25 | 2008-05-15 | Joseph Perechocky | Protective Dental Balm and Method |
US20060239938A1 (en) * | 2005-04-25 | 2006-10-26 | Joseph Perechocky | Dental balm and method of prevention of damage to teeth |
JP2009143874A (en) * | 2007-12-17 | 2009-07-02 | Chisso Corp | Oral care product |
KR101039802B1 (en) * | 2008-10-08 | 2011-06-09 | 주식회사 나이벡 | A Composition for Teeth Desensitizing |
GB0822434D0 (en) * | 2008-12-09 | 2009-01-14 | Glaxo Group Ltd | Novel use |
US8658139B1 (en) | 2010-02-27 | 2014-02-25 | Squigle, Inc. | Prevention and treatment of oral diseases |
US9717929B2 (en) * | 2010-12-07 | 2017-08-01 | Colgate-Palmolive Company | Dentifrice compositions containing calcium silicate and a basic amino acid |
SG190974A1 (en) | 2010-12-23 | 2013-07-31 | Colgate Palmolive Co | Aqueous oral care composition comprising xanthan gum, cellulose gum and carbomer |
US11147751B2 (en) | 2010-12-23 | 2021-10-19 | Colgate-Palmolive Company | Fluid compositions comprising a structuring agent |
JP5179626B2 (en) * | 2011-06-13 | 2013-04-10 | 花王株式会社 | Dentifrice composition |
JP6038567B2 (en) * | 2012-09-21 | 2016-12-07 | 花王株式会社 | Oral composition |
JP6092751B2 (en) | 2013-10-25 | 2017-03-08 | ライオン株式会社 | Dentifrice composition |
GB201322510D0 (en) * | 2013-12-19 | 2014-02-05 | Glaxo Group Ltd | Novel composition |
JP6276028B2 (en) * | 2013-12-27 | 2018-02-07 | 花王株式会社 | Oral composition for dentin hypersensitivity |
GB201621685D0 (en) * | 2016-12-20 | 2017-02-01 | Glaxosmithkline Consumer Healthcare (Uk) Ip Ltd | Novel composition |
EP3381516A1 (en) * | 2017-03-29 | 2018-10-03 | Koninklijke Philips N.V. | Oral care particles and system for the administration thereof |
US11529295B2 (en) | 2019-09-25 | 2022-12-20 | Church & Dwight Co., Inc. | Oral care composition |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4847070A (en) * | 1987-10-08 | 1989-07-11 | The Procter & Gamble Company | Anticalculus compositions |
US4871531A (en) * | 1986-02-10 | 1989-10-03 | Hartlaub Gregory R | Oral compositions |
US4965067A (en) * | 1988-08-10 | 1990-10-23 | The Proctor & Gamble Company | Oral compositions |
US5240697A (en) * | 1991-10-17 | 1993-08-31 | Colgate-Palmolive Company | Desensitizing anti-tartar dentifrice |
US5270031A (en) * | 1991-12-20 | 1993-12-14 | Block Drug Company Inc. | Dentinal desensitizing compositions |
US5688492A (en) * | 1992-05-22 | 1997-11-18 | The Boots Company Plc, | Oral hygiene composition |
US6096292A (en) * | 1998-07-28 | 2000-08-01 | Block Drug Company, Inc. | Polymeric desensitizing compositions |
US6099315A (en) * | 1996-09-20 | 2000-08-08 | Block Drug Company, Inc. | Applicator tip for desensitizing agents and method |
US6241972B1 (en) * | 1999-02-19 | 2001-06-05 | Block Drug Company, Inc. | Oral care formulation for the treatment of sensitivity teeth |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3122483A (en) * | 1960-07-21 | 1964-02-25 | Block Drug Co | Strontium ion toothpaste |
US3863006A (en) * | 1973-01-29 | 1975-01-28 | Milton Hodosh | Method for desensitizing teeth |
JP3793621B2 (en) * | 1997-04-25 | 2006-07-05 | 花王株式会社 | Perceptual oral composition |
US8840918B2 (en) * | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
-
2001
- 2001-08-21 EP EP01966037A patent/EP1331919A4/en not_active Ceased
- 2001-08-21 AR ARP010103970A patent/AR030713A1/en unknown
- 2001-08-21 CA CA002420154A patent/CA2420154A1/en not_active Abandoned
- 2001-08-21 US US10/344,074 patent/US20030215401A1/en not_active Abandoned
- 2001-08-21 JP JP2002520724A patent/JP2004506663A/en active Pending
- 2001-08-21 WO PCT/US2001/026073 patent/WO2002015809A2/en active Application Filing
- 2001-08-21 AU AU2001286581A patent/AU2001286581A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4871531A (en) * | 1986-02-10 | 1989-10-03 | Hartlaub Gregory R | Oral compositions |
US4847070A (en) * | 1987-10-08 | 1989-07-11 | The Procter & Gamble Company | Anticalculus compositions |
US4965067A (en) * | 1988-08-10 | 1990-10-23 | The Proctor & Gamble Company | Oral compositions |
US5240697A (en) * | 1991-10-17 | 1993-08-31 | Colgate-Palmolive Company | Desensitizing anti-tartar dentifrice |
US5270031A (en) * | 1991-12-20 | 1993-12-14 | Block Drug Company Inc. | Dentinal desensitizing compositions |
US5597552A (en) * | 1991-12-20 | 1997-01-28 | Block Drug Company Inc. | Dentinal desensitizing compositions |
US5653964A (en) * | 1991-12-20 | 1997-08-05 | Block Drug Company Inc. | Dentinal desensitizing compositions |
US5688492A (en) * | 1992-05-22 | 1997-11-18 | The Boots Company Plc, | Oral hygiene composition |
US6099315A (en) * | 1996-09-20 | 2000-08-08 | Block Drug Company, Inc. | Applicator tip for desensitizing agents and method |
US6096292A (en) * | 1998-07-28 | 2000-08-01 | Block Drug Company, Inc. | Polymeric desensitizing compositions |
US6241972B1 (en) * | 1999-02-19 | 2001-06-05 | Block Drug Company, Inc. | Oral care formulation for the treatment of sensitivity teeth |
Non-Patent Citations (1)
Title |
---|
See also references of EP1331919A2 * |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1390004A4 (en) * | 2001-05-03 | 2004-08-04 | Block Drug Co | Dental composition for treating hypersensitive teeth |
EP1390004A2 (en) * | 2001-05-03 | 2004-02-25 | Block Drug Company, Inc. | Dental composition for treating hypersensitive teeth |
EP2281550A3 (en) * | 2003-02-21 | 2012-07-18 | Rhodia, Inc. | Anti sensitivity, anti-caries, anti-staining, anti-plaque, ultra-mild oral hygiene agent |
EP1599182A2 (en) * | 2003-02-21 | 2005-11-30 | Rhodia Inc. | Anti-sensitivity, anti-caries, anti-staining, anti-plaque, ultra-mild oral hygiene agent |
EP1599182A4 (en) * | 2003-02-21 | 2008-08-20 | Rhodia | Anti-sensitivity, anti-caries, anti-staining, anti-plaque, ultra-mild oral hygiene agent |
CN1750807B (en) * | 2003-02-21 | 2010-05-12 | 罗迪亚公司 | Anti-sensitivity, anti-caries, anti-staining, anti-plaque, ultra-mild oral hygiene agent |
US7090882B2 (en) | 2003-06-12 | 2006-08-15 | Cargill, Incorporated | Antimicrobial salt solutions for food safety applications |
WO2006100071A1 (en) | 2005-03-21 | 2006-09-28 | Glaxo Group Limited | Alkyl sulfate free and orthophosphate free dentifrice compostion comprising a fluoride source and a silica dental abrasive |
US9554975B2 (en) | 2005-03-21 | 2017-01-31 | Glaxo Group Limited | Alkyl sulfate free and orthophosphate free dentifrice composition comprising fluoride source and a silica dental abrasive |
US8900558B2 (en) | 2006-06-30 | 2014-12-02 | Colgate-Palmolive Company | High fluoride ion oral care composition and method for maintaining anticaries activity |
WO2009106972A2 (en) * | 2008-02-26 | 2009-09-03 | Italmed S.R.L. | Dental composition for desensitizing, disinfecting and protecting exposed dentine |
WO2009106972A3 (en) * | 2008-02-26 | 2009-10-22 | Italmed S.R.L. | Dental composition for desensitizing, disinfecting and protecting exposed dentine |
RU2526148C2 (en) * | 2008-09-30 | 2014-08-20 | Глаксо Груп Лимитед | Toothpaste composition |
US9937365B2 (en) | 2009-04-01 | 2018-04-10 | Colgate-Palmolive Company | Dual action dentifrice compositions to prevent hypersensitivity and promote remineralization |
EP2413882B1 (en) | 2009-04-01 | 2016-11-16 | Colgate-Palmolive Company | Dual action dentifrice compositions to prevent hypersensitivity and promote remineralization |
WO2010112577A1 (en) | 2009-04-03 | 2010-10-07 | Glaxo Group Limited | Antibacterial composition comprising 4 -isopropyl-3-methylpheno and zinc ions |
WO2011009867A2 (en) | 2009-07-22 | 2011-01-27 | Glaxo Group Limited | Novel composition |
WO2011073229A1 (en) | 2009-12-17 | 2011-06-23 | Glaxo Group Limited | Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity |
WO2011120943A2 (en) | 2010-03-31 | 2011-10-06 | Glaxo Group Limited | Novel composition |
WO2013020960A2 (en) | 2011-08-09 | 2013-02-14 | Glaxo Group Limited | Novel composition |
WO2013034196A1 (en) * | 2011-09-09 | 2013-03-14 | Gaba International Holding Ag | Stable compositions and methods for preparing the same |
US9320691B2 (en) | 2011-09-09 | 2016-04-26 | GABA International Holdings AG | Stable compositions and methods for preparing the same |
WO2014124950A1 (en) | 2013-02-14 | 2014-08-21 | Glaxo Group Limited | Novel composition |
AU2014342543B2 (en) * | 2013-10-28 | 2017-03-09 | The Procter & Gamble Company | Oral care compositions for tooth desensitizing |
WO2015065968A1 (en) * | 2013-10-28 | 2015-05-07 | The Procter & Gamble Company | Oral care compositions for tooth desensitizing |
RU2670432C2 (en) * | 2013-10-28 | 2018-10-23 | Дзе Проктер Энд Гэмбл Компани | Oral care compositions for tooth desensitising |
CN106794132A (en) * | 2014-08-29 | 2017-05-31 | 日油株式会社 | Dental hypersensitiveness's mitigation oral cavity composition |
EP3187169A4 (en) * | 2014-08-29 | 2018-02-21 | NOF Corporation | Oral composition for alleviation of dentin hypersensitivity |
WO2019068596A1 (en) | 2017-10-02 | 2019-04-11 | Glaxosmithkline Consumer Healthcare (Uk) Ip Limited | Novel composition |
WO2019115601A1 (en) | 2017-12-15 | 2019-06-20 | Glaxosmithkline Consumer Healthcare (Uk) Ip Limited | Novel composition |
WO2020007888A1 (en) | 2018-07-05 | 2020-01-09 | Glaxosmithkline Consumer Healthcare (Uk) Ip Limited | Dentifrice comprising carboxylic acid or alkali metal salt thereof and a source of free fluoride ions |
WO2020007887A1 (en) | 2018-07-05 | 2020-01-09 | Glaxosmithkline Consumer Healthcare (Uk) Ip Limited | Dentifrice comprising a pvm-ma copolymer and a source of free fluoride ions |
WO2023094489A1 (en) | 2021-11-29 | 2023-06-01 | Glaxosmithkline Consumer Healthcare (Uk) Ip Limited | Non-aqueous dentifrice composition |
Also Published As
Publication number | Publication date |
---|---|
EP1331919A2 (en) | 2003-08-06 |
AU2001286581A1 (en) | 2002-03-04 |
AR030713A1 (en) | 2003-09-03 |
JP2004506663A (en) | 2004-03-04 |
CA2420154A1 (en) | 2002-02-28 |
US20030215401A1 (en) | 2003-11-20 |
WO2002015809A3 (en) | 2002-06-06 |
EP1331919A4 (en) | 2005-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030215401A1 (en) | Dental composition for hypersensitve teeth | |
US20070059257A1 (en) | Dentinal composition for hypersensitive teeth | |
US6416745B1 (en) | Dental composition for treating hypersensitive teeth | |
AU2001296802B2 (en) | Anhydrous dentifrice formulations for the delivery of incompatible ingredients | |
CA2755798C (en) | Oral compositions for treating tooth sensitivity and methods of use and manufacture thereof | |
JP5782429B2 (en) | Oral composition containing polyguanidinium compound, method of manufacture and use thereof | |
RU2337734C2 (en) | Ultrasoft agent for hygienic oral cavity care to prevent sensitivity, caries, staining and dental deposit | |
US8790707B2 (en) | Surface-treated calcium phosphate particles suitable for oral care and dental compositions | |
AU2010365040B2 (en) | Dentifrice compositions containing calcium silicate | |
AU2001296802A1 (en) | Anhydrous dentifrice formulations for the delivery of incompatible ingredients | |
JPH0665083A (en) | Composition for relaxing and removing dental pain supersensitivity | |
US20020041852A1 (en) | Dental composition for hypersensitive teeth | |
CN110636887A (en) | Oral care compositions and methods of use | |
US6592853B2 (en) | Dentin desensitizer containing stannous fluoride | |
US6096292A (en) | Polymeric desensitizing compositions | |
WO2014054257A1 (en) | Dentifrice composition | |
WO2024104743A1 (en) | Oral care composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10344074 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2420154 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002520724 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001966037 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001966037 Country of ref document: EP |